Objective To assess the efficacy and toxicity of Nedaplatin combined with Gemcitabine in treatment of triple negative breast cancer. Methods Totally 52 cases with TNBC were included from Sep 2010 to Dec 2014. Of the included 52 cases,21 patients were initial diagnosis and other 31 cases were recurrences patients. All of the included 52 cases received nedaplatin 80mg/ m2 ,d1 plus gemcitabine 1000mg/ m2 ,d1,8,intravenous drip with 21 days per cycle. After 4 cycles chemotherapy,the clinical efficacy and toxicity were compared be-tween the two groups. Results The objective response rate for initial treatment patients and recurrence patients with statistical difference(P <005);The profession free survival were(16. 52 ± 3. 22)months and(12. 73 ± 1. 82)month with statistical difference(P < 0. 05). Conclusion Nedaplatin combined with Gemcitabine is effective with less toxicity in the treatment of triple negative breast cancer.%目的：探讨奈达铂联合吉西他滨治疗转移性三阴性乳腺癌（TNBC）的近期疗效和不良反应。方法选择2010-09—2014-12间入住的52例 TNBC 患者作为研究对象。其中首发组患者21例，术后复发组患者31例。化疗方案为：奈达铂80 mg/ m2， d1；吉西他滨1000 mg/ m2，d1，8，静滴。每21 d 为一个化疗周期。持续两个周期后对疗效进行评价。比较2组患者近期疗效及不良反应发生情况。结果（1）首发组总缓解率显著高于术后复发组（ P <0.05）。首发组患者中位无进展生存时间（PFS）为（21.52±3.22）个月，术后复发组患者 PFS 为（16.73±1.82）个月，首发组患者 PFS 显著高于术后复发组（P <0.05）。（2）本组患者治疗过程中，主要发生的不良反应包括：贫血、中性粒细胞减少、血小板减少、恶心呕吐、腹泻、便秘、脱发、皮疹等，且不良反应毒性分级以1～2级为主。结论奈达铂联合吉西他滨治疗转移性三阴性乳腺癌（TNBC）的近期疗效显著，不良反应主要以1～2级为主。
展开▼
